Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there. Did your doctor somehow miss the recovery protocol that Pedro Bach-y-Rita used to recover fully back in 1958 with only a partial brain?

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Thursday, October 6, 2022

Vinpocetine restores cognitive and motor functions in Traumatic brain injury challenged rats

Would this work for stroke and on humans? WHOM will be doing that research? With NO leadership in stroke, no followup ever occurs. 

Well maybe there is something, ask your doctor about these results. Was not hard to find, Google scholar; 'vinpocetine stroke', that just shows you how fucking incompetent your stroke doctors and hospital are!

Vinpocetine for acute ischaemic stroke 2008

A systematic review of vinpocetine therapy in acute ischaemic stroke 1999

Anti-inflammatory effects of vinpocetine in atherosclerosis and ischemic stroke: a review of the literature 2014 

Vinpocetine inhibits NF-κB-dependent inflammation in acute ischemic stroke patients 2018 

Role of vinpocetine in ischemic stroke and poststroke outcomes: A critical review 2020 

Vinpocetine increases cerebral blood flow and oxygenation in stroke patients: a near infrared spectroscopy and transcranial Doppler study 2002  This one is incredibly important immediately post stroke. What the fuck has your incompetent hospital done with it in 20 years?

 

The latest here:

Vinpocetine restores cognitive and motor functions in Traumatic brain injury challenged rats

Abstract

Traumatic brain damage is common worldwide and the treatments are not well-defined. Vinpocetine is a synthetic derivative of the vinca alkaloid vincamine and is clinically being used for various brain disorders. Here in the current study, we have investigated the neuroprotective potential of vinpocetine against traumatic brain injury. TBI was induced by the Marmarou weight drop method in rats. Brain damage was evaluated using cognitive and motor functions and the alterations in biomolecules. Injured rats were treated with different doses of vinpocetine (2.5, 5, and 10 mg/kg) for 4 weeks. Traumatic brain injury in rats produced significant deterioration of cognition and motor functions, which was accompanied by increased oxidative stress and significant alterations in brain monoamine levels as compared with the sham control group (p < 0.05). Vinpocetine alleviated TBI-induced oxidative burden, altered neurochemistry, and improved the cognitive and motor functions as compared with that of the TBI control group (p < 0.05). The observed neuroprotective potential of vinpocetine may be due to the observed antioxidant potential and its ability to restore the levels of brain neurochemicals under stressed conditions. The outcomes of the current study may help the repositioning of vinpocetine for preventing or treating traumatic brain injuries.

This is a preview of subscription content, access via your institution.

Data availability

Enquiries about data availability should be directed to the authors

COVID-19 vaccination may enhance hippocampal neurogenesis in adults

 Since we need all the neurogenesis help we can get, this is good news.

COVID-19 vaccination may enhance hippocampal neurogenesis in adults


https://doi.org/10.1016/j.bbi.2022.09.020Get rights and content

Highlights

•

The COVID-19 infection has a detrimental impact on hippocampal neurogenesis in adults.

•

In contrast, the existing literature supports an enhancing effect of COVID-19 vaccination on hippocampal neurogenesis.

•

The COVID vaccine-induced hippocampal neurogenesis may protect against age-related cognitive decline and mental disorders.

Abstract

Emerging evidence suggests a detrimental impact of COVID-19 illness on the continued hippocampal neurogenesis in adults. In contrast, the existing literature supports an enhancing effect of COVID-19 vaccination on adult hippocampal neurogenesis. Vaccines against respiratory infections, including influenza, have been shown to enhance hippocampal neurogenesis in adult-age animals. We propose that a similar benefit may happen in COVID-19 vaccinated adults. The vaccine-induced enhancement of the hippocampal neurogenesis in adults thus may protect against age-related cognitive decline and mental disorders. It also hints at an added mental health benefit of the COVID-19 vaccination programs in adults.

Effective Management of Post-Stroke Spasticity

I most certainly will not be wasting my time on this.

'Management' NOT CURE

Effective Management of Post-Stroke Spasticity

With the aim of improving the quality of support and educational material available globally on the topic of Life After Stroke, the World Stroke Academy invites you to participate in a free 60min webinar on the ‘Management of Post-Stroke Spasticity’.
 

Speakers:

  • Diana Wong Ramos - Portugal AVC – Uniao de Sobreviventes, Familiares e Amigos (Portugal)
  • Theodore Wein - Assistant Professor of Neurology and Neurosurgery, Stroke Prevention Clinic,Montreal General Hospital, McGill University (Canada)
  • Richard Zorowitz - Chief Medical Informatics Officer, MedStar National Rehabilitation Network and Professor of Clinical Rehabilitation Medicine, Georgetown University School of Medicine (USA)

Moderator:

  • Christine Roffe, Professor of Stroke Medicine, Keele University (United Kingdom)
Description:

With the aim of improving the quality of support and educational material available globally on the topic of Life After Stroke, the World Stroke Academy, the Educational platform of the World Stroke Organization, invites you to participate in a free 60min webinar on the ‘Management of Post-Stroke Spasticity’. This webinar will be structured in 3 segments. The first one will introduce the personal experience of spasticity after stroke in a stroke survivor. The second will cover the topic of motor impairments and activity limitations after stroke and the third one will focus on the benefits of treating spasticity early.

This activity is funded by an unrestricted educational grant by Ipsen.

Chair/Moderator:

Prof. Christine Roffe (UK)

Topics and speakers:

Spasticity after stroke: my personal experience – Diana Wong Ramos (Portugal)
Motor impairments and activity limitations after stroke – Theodore Wein (Canada)
Treating spasticity early: what are the benefits? – Richard Zorowitz (USA)
Date and time:

2 PM CET on 11th October, 2022

  •  

Midlife Omega-3 Levels Tied to Brain Structure, Cognition

What is your doctor doing to test for this and what protocol exists to make sure you are ingesting the right amounts? Since I'm going to live to 100, I'm in midlife at age 66 right now.

But all this risk for your doctor to explain:

Routine fish oil supplementation increases risk for incident AF

But this:

Fish oils do not prevent heart attack or strokes in people with diabetes

August 2018

And this:

Study: Fish Oil Supplements May Not Combat Stroke

March 2018 

And this:

Long-term consumption of sunflower and fish oils damages the liver

January 2018

And this:

Omega-3 Fatty Acid Supplementation and Warfarin: A Lethal Combination in Traumatic Brain Injury

 

The latest here:

Midlife Omega-3 Levels Tied to Brain Structure, Cognition

Larger hippocampal volume, better abstract reasoning for people in their 40s

A photo of foods high in Omega 3 fatty acids including, salmon, nuts, broccoli, olive oil, seeds.

Omega-3 fatty acid concentrations in red blood cells were linked with brain structure and cognitive function in midlife, an exploratory cross-sectional study showed.

In about 2,200 people with an average age of 46, a higher omega-3 index was associated with a larger hippocampal volume and better abstract reasoning, according to Claudia Satizabal, PhD, of the University of Texas Health Science Center at San Antonio, and colleagues.

In addition, APOE4 carriers with a higher omega-3 index had a lower white matter hyperintensity burden, they reported in Neurology.

The omega-3 index combined docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) concentrations measured by gas chromatography.

The study is one of the first to identify relationships between omega-3 polyunsaturated fatty acids (PUFA), like DHA and EPA, and brain health in a younger population.

"The new contribution here is that, even at younger ages, if you have a diet that includes some omega-3 fatty acids, you are already protecting your brain for most of the indicators of brain aging that we see at middle age," Satizabal said in a statement.

Omega-3 fatty acids are obtained largely from dietary sources like cold-water, oily fish or omega-3 fortified foods, or through nutritional supplements. In the brain, DHA is incorporated into neuronal and glial cell membranes. Both DHA and EPA are metabolized into bioactive molecules involved in neurogenesis, neurotransmission, and inflammation resolution.

In older adults, observational studies have suggested that higher DHA and EPA intake may be protective for Alzheimer's disease. Omega-3 fatty acid levels also may protect older brains from environmental exposures like air pollution. Studies have linked pro-inflammatory diets, which are low in omega-3s, to brain volume and other markers of brain aging in older people.

"Despite the beneficial associations observed for brain outcomes in population-based and experimental studies, results from dietary intervention studies using omega-3 PUFA supplementation have been inconsistent," Satizabal and colleagues pointed out.

"These studies may be hampered in part by interventions that are deemed too late in the course of the disease, when individuals may have already experienced significant neuronal damage," they noted.

The researchers evaluated 2,183 predominantly middle-aged people in the Framingham Heart Study Third-Generation and Omni 2 cohorts who were dementia-free and stroke-free at baseline. Overall, 53% were women and 22% were APOE4 carriers.

Participants had brain MRI and cognitive function tests for episodic memory, processing speed, executive function, and abstract reasoning.

Higher levels of all omega-3 predictors -- EPA, DHA, and the omega-3 index -- were linked with larger hippocampal volumes when modeled continuously. Every standard deviation unit increase of log-transformed omega-3 index was related to 0.003 cm3 larger hippocampal volume relative to intracranial volume. Associations between higher omega-3 PUFA and larger hippocampal volumes remained significant after accounting for vascular risk factors.

All three omega-3 predictors were tied to better abstract reasoning test scores. Participants in the top three quartiles of EPA levels had better abstract reasoning performance than those in the bottom EPA quartile. Again, associations remained after adjusting for vascular risk factors.

Higher levels of all omega-3 predictors also were linked with reduced white matter hyperintensity volume in APOE4 carriers. Increasing EPA levels were tied to better performance in abstract reasoning tests in APOE4 carriers, but not in non-carriers.

The findings suggest that modest omega-3 consumption may be enough to preserve brain function, the researchers noted. "This is in line with the current American Heart Association dietary guidelines to consume at least two servings of fish per week to improve cardiovascular health," Satizabal said.

"These results need to be confirmed with additional research, but it's exciting that omega-3 levels could play a role in improving cognitive resilience, even in middle-aged people," she added.

Limitations include a largely white population in the study cohort and the cross-sectional design of the study, which provided only a snapshot in time, the researchers acknowledged.

  • Judy George covers neurology and neuroscience news for MedPage Today, writing about brain aging, Alzheimer’s, dementia, MS, rare diseases, epilepsy, autism, headache, stroke, Parkinson’s, ALS, concussion, CTE, sleep, pain, and more. Follow

Disclosures

The study was supported by the National Heart, Lung, and Blood Institute, National Institute on Aging, and National Institute of Neurological Disorders and Stroke.

Satizabal disclosed no relationships with industry. Co-authors disclosed relationships with Novartis Pharmaceuticals, OmegaQuant Analytics, Brainspan, Eisai, and Biogen.

Wednesday, October 5, 2022

Accuracy and comparison of sensor-based gait speed estimations under standardized and daily life conditions in children undergoing rehabilitation

I would expect a competent hospital to immediately bring this in to objectively diagnose stroke survivors walking problems so appropriate EXACT PROTOCOLS  can be applied to correct those problems.  There is no best case scenario since your hospital won't see this and won't do anything anyway.

Accuracy and comparison of sensor-based gait speed estimations under standardized and daily life conditions in children undergoing rehabilitation

Abstract

Background

Gait speed is a widely used outcome measure to assess the walking abilities of children undergoing rehabilitation. It is routinely determined during a walking test under standardized conditions, but it remains unclear whether these outcomes reflect the children's performance in daily life. An ankle-worn inertial sensor provides a usable opportunity to measure gait speed in the children's habitual environment. However, sensor-based gait speed estimations need to be accurate to allow for comparison of the children's gait speed between a test situation and daily life. Hence, the first aim of this study was to determine the measurement error of a novel algorithm that estimates gait speed based on data of a single ankle-worn inertial sensor in children undergoing rehabilitation. The second aim of this study was to compare the children’s gait speed between standardized and daily life conditions.

Methods

Twenty-four children with walking impairments completed four walking tests at different speeds (standardized condition) and were monitored for one hour during leisure or school time (daily life condition). We determined accuracy by comparing sensor-based gait speed estimations with a reference method in both conditions. Eventually, we compared individual gait speeds between the two conditions.

Results

The measurement error was 0.01 ± 0.07 m/s under the standardized and 0.04 ± 0.06 m/s under the daily life condition. Besides, the majority of children did not use the same speed during the test situation as in daily life.

Conclusion

This study demonstrates an accurate method to measure children's gait speed during standardized walking tests and in the children's habitual environment after rehabilitation. It only requires a single ankle sensor, which potentially increases wearing time and data quality of measurements in daily life. We recommend placing the sensor on the less affected side, unless the child wears one orthosis. In this latter case, the sensor should be placed on the side with the orthosis. Moreover, this study showed that most children did not use the same speed in the two conditions, which encourages the use of wearable inertial sensors to assess the children's walking performance in their habitual environment following rehabilitation.


Rehabilitation After Stroke: Current State of the Science

In my view stroke rehab is a complete disaster and I've seen nothing that suggests the ensuing 12 years have improved it. Everything in stroke is a shitshow!

 0. There is no fast, easy and objective way to diagnose a stroke.
1. tPA may save your life with tPA having a 88% failure rate for full recovery.
2. Your neurologist doesn't have any concrete stroke protocols to save all the neurons that are dying in the first week.
3. Your neurologist or physiatrist doesn't have any clue about how to get you to full recovery. (Ask them exactly how to do it), you'll get excuses.
4. Only 10% get to full recovery..
5. No protocols to prevent your 33% dementia chance post-stroke from an Australian study.
6. Nothing to alleviate your fatigue.
7. Nothing that will cure your spasticity.
8. Nothing on cognitive training unless you find this yourself.
9. No published stroke protocols.
10. No way to compare your stroke hospital results vs. other stroke hospitals.
Everything in stroke is a complete failure. 

Rehabilitation After Stroke: Current State of the Science

Abstract

Stroke rehabilitation is evolving into a clinical field based on the neuroscience of recovery and restoration. There has been substantial growth in the number and quality of clinical trials performed. Much effort now is directed toward motor restoration and is being led by trials of constraint-induced movement therapy. Although the results do not necessarily support that constraint-induced movement therapy is superior to other training methods, this treatment has become an important vehicle for developing clinical trial methods and studying the physiology underlying activity-based rehabilitation strategies. Other promising interventions include robotic therapy delivery, magnetic and electrical cortical stimulation, visualization, and constraint-driven aphasia therapies. Amphetamine has not been demonstrated to be effective, and studies of other pharmacologic agents are still preliminary. Future studies will incorporate refinements in clinical trial methods and improved activity- and technology-based interventions.

Can Erectile Dysfunction Drugs Reduce Dementia Risk?

But all this earlier research, isn't your doctor already prescribing Viagra?

So inconsistencies, WHOM  is going to do the followup research to get a definitive answer?  Ask your doctor what is the downside of doing this prior to complete results?  I'd do almost anything to reduce the chances of dementia after seeing my Dad have it.

For your stroke edification. And for the women:

FDA Approves 'Female Viagra' Amid Cheers and Jeers August 2015.

18 posts on Viagra here.

Impotence medicine associated with reduced long-term risk of death after heart attack March 2017 

Drugs used for impotence could treat vascular dementia?  December 2014 

This made it sound helpful, even though it was just in rats and during the first week:  viagra and stroke rehab March 2011

Sildenafil Enhances Neurogenesis and Oligodendrogenesis in Ischemic Brain of Middle-Aged Mouse November 2012

 

 

Viagra may one day help treat heart disease. Here’s why March 2019

The latest here.

 

Can Erectile Dysfunction Drugs Reduce Dementia Risk?

— DREAM study findings conflict with other recent data

Last Updated October 5, 2022
 A photo of the packaging and blisterpacks of Cialis and Viagra over a computer rendering of amyloid plaques.

New research failed to support the hypothesis that phosphodiesterase-5 (PDE5) inhibitors like sildenafil (Viagra) and tadalafil (Cialis) are promising drug repurposing candidates for Alzheimer's disease and dementia.

Using four analytic approaches designed to address potential biases, PDE5 inhibitors did not reduce the risk of Alzheimer's and related dementia compared with other drugs used for pulmonary arterial hypertension (PAH), showed Rishi Desai, MS, PhD, of Brigham and Women's Hospital and Harvard Medical School in Boston, and colleagues.

The findings, published in Brain Communications, are part of the ongoing NIH DREAM (Drug Repurposing for Effective Alzheimer's Medicines) initiative.

PDE5 inhibitors work by relaxing smooth muscle cells. Sildenafil and tadalafil are approved treatments for erectile dysfunction and PAH.

The new DREAM study findings conflict with a recent analysis in Nature Aging that suggested sildenafil users were 69% less likely to develop Alzheimer's disease than non-sildenafil users.

"Major differences in the design of these two investigations likely explain this inconsistency," co-author Madhav Thambisetty, MD, PhD, of the National Institute on Aging, told MedPage Today.

In the Nature Aging analysis, Feixiong Cheng, PhD, of the Cleveland Clinic Genomic Medicine Institute, and colleagues compared the risk of incident Alzheimer's disease in sildenafil users against people who used antihypertensive agents or type 2 diabetes drugs.

"This design choice is likely to result in comparison of individuals with erectile dysfunction -- which is by far the most common indication for sildenafil -- to generally older individuals with diabetes or hypertension," Thambisetty observed.

"Since worse cardiometabolic health is a well-recognized risk factor for Alzheimer's disease, and seeking treatment for erectile dysfunction is likely reflective of a certain level of preserved physical and cognitive function, we believe that results from [Cheng's group] can be at least partly explained by severe confounding by indication," he pointed out.

"We restricted our analyses to an alternative indication for PDE5 inhibitors -- PAH -- and selected an equivalent comparator drug that is used for the same indication to minimize confounding by indication," Thambisetty stated.

In rodents, sildenafil has been shown to improve memory and cognitive function, help synaptic plasticity and learning, and reduce amyloid burden. Tadalafil also has improved memory and learning and lowered amyloid in rodents. "However, results in human studies have been inconsistent," Desai and colleagues noted.

Using Medicare fee-for-service claims data from 2007 through 2018, DREAM study researchers matched 2,888 patients with PAH on PDE5 inhibitors (73.6% sildenafil, 26.4% tadalafil) with 2,888 comparable people on endothelin receptor antagonists.

Mean age of the cohort was 74, and 69% were women. Overall, 90% had hypertension, 72% had heart failure, and 43% had atrial fibrillation.

The research group used four analytic approaches to counter possible biases like informative censoring, reverse causality, and outcome misclassification:

  • An as-treated follow-up approach
  • An as-started follow-up approach with a 6-month induction period
  • An approach that incorporated a 6-month symptoms-to-diagnosis period
  • An approach using a high-specificity outcome definition of dementia

In all four analyses, PDE5 inhibitors were not associated with reduced risk for Alzheimer's and dementia. Hazard ratios were 0.99 (95% CI 0.69–1.43), 1.00 (95% CI 0.71–1.42), 0.67 (95% CI 0.43–1.06), and 1.15 (95% CI 0.57–2.34), respectively.

The researchers also tested whether sildenafil had effects on cell culture-based Alzheimer's models and found no evidence that the drug corrected molecular abnormalities associated with Alzheimer's disease.

The study may have been underpowered to detect differences of small magnitude, Desai and colleagues noted. Evaluating people with PAH allowed for unbiased comparisons of treatment effects, but this population is atypical with a high underlying cardiometabolic disease burden, they acknowledged.

Nonetheless, "electronic health records in large real-world clinical datasets are important tools to test hypotheses about plausible drug targets in Alzheimer's disease and related dementias," Thambisetty said.

Previous results from the DREAM initiative have shown that tumor necrosis factor inhibitors for rheumatoid arthritis were linked with a lower risk of Alzheimer's and dementia in people with cardiovascular disease.

  • Judy George covers neurology and neuroscience news for MedPage Today, writing about brain aging, Alzheimer’s, dementia, MS, rare diseases, epilepsy, autism, headache, stroke, Parkinson’s, ALS, concussion, CTE, sleep, pain, and more. Follow

Disclosures

The DREAM study is funded by the intramural program of the National Institute on Aging.

Desai disclosed relationships with Bayer, Vertex, and Novartis. Co-authors dislcosed relationships with Bristol-Myers Squibb, Merck, Pfizer, Lilly, Intra-Cellular Therapies, Eisai, Boehringer Ingelheim, Aetion, Roche, AbbVie, Danisco, and Med Tech Epi.

Primary Source

Brain Communications

Source Reference: Desai RJ et al "No association between initiation of phosphodiesterase-5 inhibitors and risk of incident Alzheimer's disease and related dementia: Results from the Drug Repurposing for Effe

Burke Rehabilitation Hospital Honored by Newsweek

Big fucking whoopee.

 

 But you tell us NOTHING ABOUT RESULTS. They remind us they 'care' about us multiple times but never tell us how many 100% recovered.  You have to ask yourself why they are hiding their incompetency by not disclosing recovery results. ARE THEY THAT FUCKING BAD?

Anytime I see the word 'care' in stroke I know that we don't have the right goals anywhere in stroke. 100% recovery is the only goal in stroke. NOT 'care'.

 

Three measurements will tell me if the stroke hospital is possibly not completely incompetent; DO YOU MEASURE ANYTHING?  I would start cleaning the hospital by firing the board of directors, you can't let incompetency continue for years at a time.

There is no quality here if you don't measure the right things.

  1. tPA full recovery? Better than 12%?
  2. 30 day deaths? Better than competitors?
  3. rehab full recovery? Better than 10%?

 

You'll want to know results so call Dr. Mooyeon Oh-Park, SVP and Chief Medical Officer for RESULTS Phone: (914) 597 2500 . She is very accomplished so she should know these statistics off the top of her head. They are; tPA efficacy, 30 day deaths, 100% recovery. Because there is no point in going to that hospital if they are not willing to publish results.

The invalid chest thumping here:

Burke Rehabilitation Hospital Honored by Newsweek

Burke was particularly recognized for its 'Standout Program' in stroke rehabilitation.

Burke Rehabilitation Hospital, a member of the Montefiore Health System, announced it has been named to America’s Best Physical Rehabilitation Centers 2022 by Newsweek. This prestigious award recognizes excellence among inpatient rehabilitation facilities throughout the United States.

Burke is one of only nine facilities in New York State to achieve the recognition and the only one in Westchester County.

“Burke is proud to be recognized as one the most highly regarded physical rehabilitation facilities in the country,” Burke’s Executive Director Scott Edelman said. “Our clinical teams approach, deep expertise and commitment to delivering the highest quality care underpin this honor. We are committed to ensuring that each patient’s experience is the best it can be and serving our communities by continuously earning this hard-won accolade.”

Burke was particularly recognized for its ‘Standout Program’ in stroke rehabilitation. It serves about 1,000 stroke rehabilitation patients per year, more than any other hospital in New York State.

Dr. Mooyeon Oh-Park, SVP and Chief Medical Officer, commented, “Our stroke program is an outstanding example of our patient care model. Close liaisons with stroke centers at acute care hospitals allow us to bring in patients faster and begin rehabilitation with minimal delay, an important factor in recovery. Our state-of-the-art rehabilitation gyms, staffed by experts in complex rehabilitation, afford our patients every advantage in the recovery process.” She concluded, “Patients are cared for by dedicated multidisciplinary teams that hold the patients’ and families’ best interests at heart.”

Prolonged DMT Infusions could be a Breakthrough for Stroke Patients

Your doctor should have been following this for years. How are they going to incorporate this into their stroke rehab protocols? They should be planning for this NOW!  Unless you're giving them a pass to be incompetent for life.  

  • DMT (7 posts to November 2020)

Prolonged DMT Infusions could be a Breakthrough for Stroke Patients

Stroke recovery requires stimulating neuroplasticity to heal brain trauma, and prolonged DMT infusions may help speed this process

Every forty seconds in the United States, someone experiences a stroke. Strokes represent the third leading cause of death and disability globally, with billions of dollars funneled into long-term health care services, rehabilitation and support to individuals for stroke survivors. Conventional stroke treatments often fail and long-term rehabilitation can be lengthy and intensive. In other words, a novel approach to stroke treatment and recovery is timely.

Enter Algernon Pharmaceuticals. In September, 2022, the company announced that they would be carrying out a Phase 1 clinical study investigating the use of slow-release intravenous DMT infusions for stroke patients.

“Hundreds of drugs have failed in the stroke treatment space, and nearly all of them have focused on the same strategy: a delayed attempt at neuroprotection,” explained Dr. David Nutt, Professor of Neuropsychopharmacology at Imperial College London and Algernon consultant.

“Algernon’s approach with DMT is to bolster the brain’s natural recovery by enhancing neuroplasticity to facilitate the creation of new neural networks. This is something completely different than what has been tried before.”

The rationale for using DMT for stroke patients

N,N-dimethyltryptamine, or DMT, is a psychedelic compound that produces similar effects to LSD and psilocybin. However, DMT differs from other psychedelics in the rapidity and intensity of its onset and effects, delivering a near instantaneous, visually intense trip that can last from 30 to 45 minutes. This potent psychedelic is produced by diverse plant and animal species and is also an endogenous hallucinogen found in the human body.

Evidence suggests that DMT may offer unique therapeutic benefits as a stroke treatment. Strokes represent a form of brain injury. The most common type of stroke, ischemic strokes, are often caused by clots that block critical blood flow to the brain. Brain cells can become damaged or can even die if blood flow is inhibited for a long time. However, strokes can also injure the brain in other ways. Neuroinflammation occurs following a stroke, largely due to reperfusion injury. Reperfusion takes place when the blood supply returns to the oxygen-deprived brain tissue, paradoxically causing tissue damage.

DMT has been well-studied with respect to its effects on neuroinflammation and reperfusion injury. The potential that DMT holds in this space is promising, particularly because there are currently no conventional, highly effective medical therapies for strokes that address reperfusion. DMT can offer protective effects after reperfusion injury and also stimulate cell growth and enhance neuroplasticity. Neuroplasticity is the process by which the brain forms new synaptic connections in response to learning, experience or injury. This combination of tissue protection, cellular growth and enhanced neuroplasticity may therefore be a game changer for stroke patients.

“In a rat stroke occlusion study, rats given DMT showed reduction in the area of brain damage from the stroke and had almost a full recovery of motor function when compared to control,” said Christopher Moreau, CEO of Algernon. “In a preclinical research study at UC Davis, DMT increased neuroplasticity in a cortical neuron growth assay.”

Moreau believes that DMT represents a novel way to promote healing and recovery after an ischemic stroke.

“For 85% of patients suffering an ischemic stroke, which constitute 85% of all strokes, there are no treatment options,” reflected Moreau. “Hundreds of stroke drugs have failed in the clinic but have been focused on neuroprotective measures, whereas DMT represents a different approach to stroke treatment, helping with healing after the injury occurs.”

Algernon has also been exploring the viability of DMT as a treatment for stroke for over a year. The company’s earlier preclinical research found that sub-hallucinogenic doses of DMT stimulated neuron cell growth by 40%. Their upcoming clinical research will be focused on studying the effects on sub-hallucinogenic doses on human participants.

“My work with DMT in the 1990s demonstrated that psychedelic drugs can be safely studied in humans and established a framework for investigations into the therapeutic benefits of the entire class,” said Rick Strassman MD, Algernon consultant, psychiatrist, psychopharmacologist, and author of DMT: The Spirit Molecule.

“Groups testing these agents in psychiatric disorders are manifold, but Algernon’s decision to explore the potential benefits of DMT’s neuroplastogenic effects in stroke is a unique and especially exciting strategy.”

Algernon’s landmark stroke study

Algernon’s Phase I stroke study will kick off in the last few months of 2022 in the Netherlands, testing the safety, tolerability and pharmacokinetics of DMT on up to 60 volunteers. What makes the study particularly unique is that DMT will be administered as a prolonged infusion for durations that have never before been clinically studied. For stroke patients, treatment is a race against the clock. Brain cells can begin to die within five minutes of blood supply being shut off. Prolonged intravenous infusion allows DMT to enter the bloodstream immediately and remain circulating in the body.

“The fastest way to deliver a drug and maximize the dose is through either a bolus dose or long duration intravenous delivery method because it bypasses the stomach and liver,” explained Moreau.

“Algernon will be delivering a sub-psychedelic dose to patients over a range of multiple time periods. This approach has never been done before in a Phase I trial.”

The administration of sub-hallucinogenic doses to human participants is also noteworthy. According to some experts, hallucinogenic effects are necessary for some or all of psychedelics’ therapeutic effects. To date, there have been few human trials exploring the therapeutic impact of psychedelics at sub-hallucinogenic levels. Algernon’s research will provide valuable insights into the specific therapeutic actions of sub-hallucinogenic doses of DMT on people –albeit using novel forms of DMT.

The brand has filed patent applications for novel salt forms of DMT, along with dosing, formulation and method of use applications. A novel salt form of DMT is considered a separate structure from the original compound, and can therefore be patented. Salts can be used to improve the core drug rendering it more stable, tolerable, safer, or even more effective.

The first part of the study will use a single-escalating dose design to determine a safe, tolerable dose that will not produce psychedelic effects. The second part of the study will test the effects of repeated, prolonged administrations at this dose. The sixty participants will be a mixture of psychedelic-naive and psychedelic-experienced healthy volunteers. Algernon plans to use data generated by the study to provide information about dosage and duration for the Phase II study, when the DMT IVF formula will be tested on acute and recovering stroke patients. Watch this space.

Tuesday, October 4, 2022

Integrity of neuronal size in the entorhinal cortex is a biologic substrate of exceptional cognitive aging

What is your doctor doing to test this in you, AND WHAT PROTOCOLS ARE GIVEN to increase this integrity. No protocols, you don't have a functioning stroke doctor.

Integrity of neuronal size in the entorhinal cortex is a biologic substrate of exceptional cognitive aging

Caren Nassif, Allegra Kawles, Ivan Ayala, Grace Minogue, Nathan P. Gill, Robert A. Shepard, Antonia Zouridakis, Rachel Keszycki, Hui Zhang, Qinwen Mao [MD, PhD], Margaret E. Flanagan [MD], Eileen H. Bigio [MD], M.-Marsel Mesulam [MD], Emily Rogalski [PhD], Changiz Geula [PhD] and Tamar Gefen [PhD]

Abstract

Average aging is associated with a gradual decline of memory capacity. SuperAgers are humans over age 80 who show exceptional episodic memory at least as good as individuals 20-30 years their junior. This study investigated whether neuronal integrity in entorhinal cortex (ERC), an area critical for memory and selectively vulnerable to neurofibrillary degeneration, differentiated SuperAgers from cognitively-healthy younger individuals, cognitively-average peers (“Normal Elderly”), and individuals with amnestic Mild Cognitive Impairment (aMCI). Postmortem sections of the ERC were stained with cresyl violet to visualize neurons, and immunostained with PHF-1 to visualize neurofibrillary tangles. The cross-sectional area (i.e., size) of layer II and layer III/V ERC neurons were quantified. Two-thirds of total participants were female. Unbiased stereology was employed to quantitate tangles in a subgroup of SuperAgers and Normal Elderly. Linear mixed-effect models were used to determine differences across groups. Quantitative measurements found the soma size of layer II ERC neurons in post-mortem brain specimens were significantly larger in SuperAgers compared to all groups (p<0.05)—including younger individuals 20-30 their junior (p<0.005). SuperAgers had significantly fewer stereologically quantified AD-related neurofibrillary tangles in layer II ERC than Normal Elderly (p<0.05). This difference in tangle burden in layer II between SuperAgers and Normal Elderly suggest that tangle-bearing neurons may be prone to shrinkage during aging. The finding that SuperAgers show ERC layer II neurons that are substantially larger even compared to individuals 20-30 years younger is remarkable, suggesting that layer II ERC integrity is a biologic substrate of exceptional memory in old age.

Every 2,000 steps a day could help keep premature death at bay

It is your doctor's responsibility to have you walking 2,000 steps a day by the time you leave the hospital. Or doesn't your doctor want to take any responsibility for your recovery? Mine didn't, he wrote 3 prescriptions for E.T.(Evaluate and Treat) to OT,PT, ST. Meaning he dumped all responsibility on the therapists. He knew nothing and did nothing.  

My numbers for steps.

10,000 Steps A Day? How Many You Really Need To Boost Longevity - 4,400

This one suggests 8900 steps a day:

Can Exercise Protect Against Alzheimer's?

 

Exactly How Many Steps You Need to Take a Day to Not Gain Weight - 15,000

Every 2,000 steps a day could help keep premature death at bay

For every 2,000 steps you take each day, your risk for premature death may fall by 8 to 11 percent, according to research published in the journal JAMA Internal Medicine.

Along with the results from a related study, published in JAMA Neurology, the researchers also found that walking more, accumulating up to roughly 10,000 steps a day, was linked to a reduction in the occurrence of cardiovascular disease (including heart disease, stroke and heart failure), 13 types of cancer and dementia.

Subscribe to The Post Most newsletter for the most important and interesting stories from The Washington Post.

Both studies involved about 78,500 participants, all middle age and older, who wore a device on their wrist to measure physical activity and whose health was monitored for a median of seven years. Taking 10,000 steps a day (roughly four to five miles, depending on a person's stride) has become a common health and fitness goal.

Video: How the pandemic rattled our eating and exercise routines

The new studies, however, found that health benefits also can be achieved by taking fewer steps. For instance, walking about 9,800 steps a day was found to lower risk of dementia by about 50 percent, but dementia risk was cut by 25 percent for those who walked as few as 3,800 steps daily.

Also, walking at a faster pace, or upping the intensity by power walking, for example, was found to have health benefits, too, with intensity amplifying the results. Walking at a faster pace was linked to a lower risk for dementia, heart disease, cancer and early death, beyond the benefit accrued for the number of daily steps.

Rehabilitation of Severe Impairment in Motor Function after Stroke: Suggestions for Harnessing the Potentials of Mirror Neurons and the Mentalizing Systems to Stimulate Recovery

 

Hopefully your doctor can use this to create protocols for your use.

 Rehabilitation of Severe Impairment in Motor Function after
Stroke: Suggestions for Harnessing the Potentials of Mirror
Neurons and the Mentalizing Systems to Stimulate Recovery

Auwal Abdullahi 1, Thomson W. L. Wong 1 and Shamay S. M. Ng 1,*
Department of Rehabilitation Sciences, Faculty of Health and Social Sciences, The Hong Kong Polytechnic
University, Hong Kong, China

*Correspondence: shamay.ng@polyu.edu.hk

Abstract  

Rehabilitation of severe impairment in motor function following stroke is very challenging. This is because one of driving forces for recovery of motor function is tasks practice, something this category of patients cannot voluntarily perform. However, it has now been shown that tasks practice can equally be carried out cognitively and through observation of another person’s practice, using techniques known as mental practice and tasks observation respectively. Mental practice and tasks observation are believed to activate networks of neurons in the brain known as mirror neurons and mentalizing systems to induce recovery. The effectiveness of these techniques has however limited evidence at the moment. One possible explanation for this could be the nature of the protocols of these techniques, especially as regards to the intensity of practice. This article proposes ways the potentials of the mirror neurons and mentalizing systems can be harnessed to optimize recovery of severe impairment in motor function using mental practice and tasks observation. The article suggests, among other ways, protocols where tasks observation or mirror therapy are carried out first, and are then followed by mental practice increasing the number of times the tasks are observed or mentalized observation of significant others performing the tasks and mentals.

Quantitative Evaluation of Biceps Brachii Muscle by Shear Wave Elastography in Stroke Patients

How is this going to get any stroke survivor better recovery? The whole point of stroke research is to get survivors recovered, this was useless for that.

Quantitative Evaluation of Biceps Brachii Muscle by Shear Wave Elastography in Stroke Patients

Authors Wei HQ, Gan M, Li GY, Ma SH, Liu JH

Received 9 February 2022

Accepted for publication 11 July 2022

Published 3 October 2022 Volume 2022:18 Pages 879—887

DOI https://doi.org/10.2147/TCRM.S361664

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Dr De-Yun Wang



Hong-Qin Wei,1 Man Gan,1 Guo-Yan Li,2 Sui-Hong Ma,1 Jian-Hua Liu1

1Department of Ultrasound, Guangzhou First People’s Hospital, Guangzhou, Guandong, People’s Republic of China; 2Department of Rehabilitation Medicine, Guangzhou First People’s Hospital, Guangzhou, Guandong, People’s Republic of China

Correspondence: Sui-Hong Ma; Jian-Hua Liu, Tel +86 13824420620 ; +86 13622888381, Fax +86 020 81332620, Email eymsh@scut.edu.cn; eyliujianhua@scut.edu.cn

Purpose: The present study aimed to investigate the differences in muscle size and shear wave speed (SWS) values of biceps brachii muscle (BBM) between stroke survivors and healthy controls.
Methods: This study comprised 61 stroke survivors and 24 healthy subjects, examined at Guangzhou First People’s Hospital within one year. Each participant underwent ultrasonic examinations for recording some specific measurement indicators, including muscle thickness, cross-sectional area (CSA), and shear wave speed (SWS) of BBM. The muscular tension of the paretic arm was scored using the modified Ashworth scale (MAS). These above-mentioned indexes were compared between stroke survivors and healthy controls. Also, the correlations among SWS and MAS scores were assessed.
Results: When the lifting arm angle was set for 45°, the CSA and muscle thickness of BBM were obviously decreased in the paretic arms of stroke subjects compared to the non-paretic arms as well as the arms of healthy controls. Moreover, the paretic arms had obviously higher SWS than the non-paretic arms and the healthy arms at 45° or 90°. When the angles of paretic arms were lifted at 90° and 45°, respectively, a positive correlation was established between MAS and SWS.
Conclusion: Ultrasonic examination assessing muscle thickness, CSA, and SWS of the BBM could be used as a means of assessment of the paretic arms of stroke survivors.

A Random Tree Forest decision support system to personalize upper extremity robot-assisted rehabilitation in stroke: a pilot study

We don't need predictions, we need EXACT PROTOCOLS THAT DELIVER RECOVERY. Are you that fucking clueless?

A Random Tree Forest decision support system to personalize upper extremity robot-assisted rehabilitation in stroke: a pilot study


Abstract:

Robotic-based rehabilitation administered by means of serious games certainly represents the frontier of rehabilitation treatments, offering a high degree of customization of therapy, to meet individual patients’ needs and to tailor a proper rehabilitation therapy. Despite the rush on developing complex rehabilitation systems, they often do not provide clinicians with long-term information about the outcome of rehabilitation, thus, not supporting them in the initial set-up phase of the therapy. In this paper, a Random-Forest based system was trained and tested to provide a prediction at discharge of several clinical scales outcomes (i.e. FMA, ARAT, and MI), having clinical scale scores and measures from the robotic system at the enrollment as inputs. The dataset includes 25 post-stroke patients from different clinics, that underwent a variable number of days of rehabilitation with a robotic treatment. Results have shown that the system is able to predict the final outcome with an accuracy ranging from 60% to 73% on the selected scales. Also results provide information on which variables are more relevant for the prediction of outcome of therapy, in particular clinical scales scores such as FMA, ARAT, MI, NRS, PCS, and MCS and robotic automatically extracted measurements related to patient’s work expenditure and time. This supports the idea of using such a system in a clinical environment in a decision support tool for clinicians.